Anavex Life Sciences Corp - Asset Resilience Ratio
Anavex Life Sciences Corp (AVXL) has an Asset Resilience Ratio of 0.07% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anavex Life Sciences Corp working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2018)
This chart shows how Anavex Life Sciences Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Anavex Life Sciences Corp assets under control.
Liquid Assets Composition Over Time
This chart breaks down Anavex Life Sciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Anavex Life Sciences Corp (AVXL) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.00K | 0.07% |
| Total Liquid Assets | $15.00K | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Anavex Life Sciences Corp maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Anavex Life Sciences Corp Industry Peers by Asset Resilience Ratio
Compare Anavex Life Sciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.58% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SHG:688266 |
Biotechnology | 0.54% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Galecto Inc
NASDAQ:GLTO |
Biotechnology | 0.00% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 0.69% |
|
Ovid Therapeutics Inc
NASDAQ:OVID |
Biotechnology | 45.65% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 14.00% |
Annual Asset Resilience Ratio for Anavex Life Sciences Corp (2014–2018)
The table below shows the annual Asset Resilience Ratio data for Anavex Life Sciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-09-30 | 0.00% | $0.00 | $24.38 Million | -- |
| 2017-09-30 | 0.00% | $0.00 | $27.84 Million | -- |
| 2016-09-30 | 0.00% | $0.00 | $9.50 Million | -- |
| 2015-09-30 | 0.00% | $0.00 | $15.47 Million | -- |
| 2014-09-30 | 0.00% | $0.00 | $7.35 Million | -- |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more